Nektar Therapeutics (NKTR) reported $29.18 million in income for the quarter ended December 2024, representing a year-over-year enhance of twenty-two.1%. EPS of -$0.15 for a similar interval compares to -$0.22 a yr in the past.
The reported income represents a shock of -25.23% over the Zacks Consensus Estimate of $39.02 million. With the consensus EPS estimate being -$0.13, the EPS shock was -15.38%.
Whereas traders scrutinize income and earnings adjustments year-over-year and the way they examine with Wall Road expectations to find out their subsequent transfer, some key metrics at all times provide a extra correct image of an organization’s monetary well being.
Since these metrics play an important function in driving the top- and bottom-line numbers, evaluating them with the year-ago numbers and what analysts estimated about them helps traders higher undertaking a inventory’s worth efficiency.
Right here is how Nektar carried out within the simply reported quarter when it comes to the metrics most generally monitored and projected by Wall Road analysts:
- Income- Product gross sales: $12.87 million versus $9.76 million estimated by eight analysts on common. In comparison with the year-ago quarter, this quantity represents a +134.8% change.
- Income- Non-cash royalty income associated to sale of future royalties: $16.24 million in comparison with the $15.15 million common estimate primarily based on eight analysts. The reported quantity represents a change of -10.1% yr over yr.
- Income- License, collaboration and different income: $0.06 million versus $28.26 million estimated by 4 analysts on common. In comparison with the year-ago quarter, this quantity represents a -81.5% change.
View all Key Company Metrics for Nektar here>>>
Shares of Nektar have returned +23.5% over the previous month versus the Zacks S&P 500 composite’s -8.2% change. The inventory at present has a Zacks Rank #2 (Purchase), indicating that it might outperform the broader market within the close to time period.
5 Shares Set to Double
Every was handpicked by a Zacks knowledgeable because the #1 favourite inventory to realize +100% or extra in 2024. Whereas not all picks might be winners, earlier suggestions have soared +143.0%, +175.9%, +498.3% and +673.0%.
Many of the shares on this report are flying underneath Wall Road radar, which supplies an incredible alternative to get in on the bottom ground.
Today, See These 5 Potential Home Runs >>
Nektar Therapeutics (NKTR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
